<div id="readability-page-1"><div>Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Corcept Therapeutics Incorporated (CORT) Misled Investors Regarding the Viability of its New Product Candidate According to the complaint, one of Corcept's lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”). During the class period, defendants represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were “powerful support” for the New Drug Application (“NDA”) that Corcept submitted to the U.S. Food and Drug Administration (“FDA”) for this indication. Defendants also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the class period, Defendants repeatedly told investors that “relacorilant is approaching approval.” Plaintiff alleges that in truth, the FDA had raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result there was a known material risk that Corcept's relacorilant NDA would not be approved. The complaint continues that on December 31, 2025, Corcept revealed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” As a result of this disclosure, the price of Corcept common stock declined from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025, or 50.4%. What Now: You may be eligible to participate in the class action against Corcept Therapeutics Incorporated. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Corcept Therapeutics Incorporated settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjAyMjAzMzUzNjVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjAyMjAzMzUzNjVyMQ"/> Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260220335365/en/</div></div>

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

醫療業 ETF - SPDR

Robbins LLP 宣佈對在 2024 年 10 月 31 日至 2025 年 12 月 30 日期間購買 Corcept Therapeutics Inc.（納斯達克：CORT）股票的投資者提起集體訴訟。訴訟指控 Corcept 在其產品候選藥物 relacorilant 治療高皮質醇血癥的可行性方面誤導了投資者。美國食品藥品監督管理局（FDA）對支持 Corcept 新藥申請的臨牀證據表示擔憂，導致在 FDA 於 2025 年 12 月 31 日發出完整回應函後，股價大幅下跌。股東可能有資格參與該集體訴訟

Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit

MorningStar

美國制藥 ETF - iShares

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

醫療業 ETF - Vanguard

基因改革 ETF - ARK

醫藥突破 ETF - ALPS

Corcept醫療

標普生物技術 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 3 倍做空 - Direxion

投資者警示：Robbins LLP 通知投資者關於 Corcept Therapeutics Inc. 的集體訴訟